5.
Sahin T, Rizzo A, Aksoy S, Guven D
. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024; 16(10).
PMC: 11120545.
DOI: 10.3390/cancers16101835.
View
6.
Butterfield L, Najjar Y
. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2023; 24(6):399-416.
PMC: 11460566.
DOI: 10.1038/s41577-023-00973-8.
View
7.
Schroeder K, Acharya L, Mani H, Furqan M, Sieren J
. Radiomic biomarkers from chest computed tomography are assistive in immunotherapy response prediction for non-small cell lung cancer. Transl Lung Cancer Res. 2023; 12(5):1023-1033.
PMC: 10261870.
DOI: 10.21037/tlcr-22-763.
View
7.
Blogowski W, Budkowska M, Salata D, Serwin K, Dolegowska B, Lokaj M
. Clinical analysis of selected complement-derived molecules in human adipose tissue. J Transl Med. 2013; 11:11.
PMC: 3570347.
DOI: 10.1186/1479-5876-11-11.
View
8.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi A
. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018; 6(1):74.
PMC: 6048712.
DOI: 10.1186/s40425-018-0383-1.
View
9.
Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J
. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8.
PMC: 4993154.
DOI: 10.1126/science.aaa1348.
View
10.
Cona M, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A
. Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers (Basel). 2019; 11(2).
PMC: 6406250.
DOI: 10.3390/cancers11020223.
View
11.
Dey A, Austin M, Kluger H, Trunova N, Mann H, Shire N
. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. Front Immunol. 2022; 13:1026964.
PMC: 9670978.
DOI: 10.3389/fimmu.2022.1026964.
View
12.
Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S
. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer. 2020; 8(2).
PMC: 7430448.
DOI: 10.1136/jitc-2020-000631.
View
13.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I
. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263.
DOI: 10.3322/caac.21834.
View
14.
Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J
. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018; 37(4):318-327.
DOI: 10.1200/JCO.2018.78.2276.
View
15.
Wang D, Wu X, Sun Y
. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022; 7(1):331.
PMC: 9485144.
DOI: 10.1038/s41392-022-01136-2.
View
16.
Ter Maat L, Van Duin I, Elias S, van Diest P, Pluim J, Verhoeff J
. Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. Eur J Cancer. 2022; 175:60-76.
DOI: 10.1016/j.ejca.2022.07.034.
View
17.
Chasseuil E, Saint-Jean M, Chasseuil H, Peuvrel L, Quereux G, Nguyen J
. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. Acta Derm Venereol. 2018; 98(4):406-410.
DOI: 10.2340/00015555-2872.
View
18.
Heeke S, Hofman P
. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. Transl Lung Cancer Res. 2018; 7(6):631-638.
PMC: 6249624.
DOI: 10.21037/tlcr.2018.08.04.
View